BNTX:NASDAQ
BioNTech SE - ADR
$96.90
arrow_upward
+0.05%(+0.050) 1D
$96.90
0.00% (0.00)
bedtimeAfter hours
Closed: Oct 2, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BNTX...
Open
$97.35
High
$98.00
Low
$96.22
Mkt. cap
24.34B
Avg. vol.
1.19M
Volume
695.83K
52-wk high
$123.98
52-wk low
$79.52
EPS
-$7.54
Beta
1.22
Shares outstanding
251.20M
No. of employees
8K
Open
$97.35
High
$98.00
Low
$96.22
Mkt. cap
24.34B
Avg. vol.
1.19M
Volume
695.83K
52-wk high
$123.98
52-wk low
$79.52
EPS
-$7.54
Beta
1.22
Shares outstanding
251.20M
No. of employees
8K
News stories
From web sources and news partners
AD HOC NEWS
·
5 hours ago
BioNTech stock after-hours at EUR 86.05: minus 0.12 percent versus prior close
AD HOC NEWS
·
7 hours ago
Morgan Stanley sets USD 115 target for BioNTech stock
AD HOC NEWS
·
1 day ago
BioNTech stock after-hours at EUR 87.00: plus 0.29 percent
Profile
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
About BioNTech SE - ADR